newsfilter
← Latest News
Business Wire·

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26